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Background: Magnesium plays an essential role in the synthesis and metabolism of vitamin D and magnesium
supplementation substantially reversed the resistance to vitamin D treatment in patients with magnesium-
dependent vitamin-D-resistant rickets. We hypothesized that dietary magnesium alone, particularly its interaction
with vitamin D intake, contributes to serum 25-hydroxyvitamin D (25(OH)D) levels, and the associations between
serum 25(OH)D and risk of mortality may be modified by magnesium intake level.
Methods: We tested these novel hypotheses utilizing data from the National Health and Nutrition Examination
Survey (NHANES) 2001 to 2006, a population-based cross-sectional study, and the NHANES III cohort, a population-
based cohort study. Serum 25(OH)D was used to define vitamin D status. Mortality outcomes in the NHANES III
cohort were determined by using probabilistic linkage with the National Death Index (NDI).
Results: High intake of total, dietary or supplemental magnesium was independently associated with significantly
reduced risks of vitamin D deficiency and insufficiency respectively. Intake of magnesium significantly interacted
with intake of vitamin D in relation to risk of both vitamin D deficiency and insufficiency. Additionally, the inverse
association between total magnesium intake and vitamin D insufficiency primarily appeared among populations at
high risk of vitamin D insufficiency. Furthermore, the associations of serum 25(OH)D with mortality, particularly due
to cardiovascular disease (CVD) and colorectal cancer, were modified by magnesium intake, and the inverse
associations were primarily present among those with magnesium intake above the median.
Conclusions: Our preliminary findings indicate it is possible that magnesium intake alone or its interaction with
vitamin D intake may contribute to vitamin D status. The associations between serum 25(OH)D and risk of mortality
may be modified by the intake level of magnesium. Future studies, including cohort studies and clinical trials, are
necessary to confirm the findings.
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Vitamin D deficiency causes rickets among children and
osteomalacia in adults [1]. Many epidemiologic studies
suggest that low vitamin D status may also be associated
with risk of non-skeletal chronic diseases, such as, all-
cause mortality [2-4], type 2 diabetes [5-7], cardiovascu-
lar diseases (CVD) [8,9], and colorectal cancer [10-12].
However, findings have not been entirely consistent
[13-16]. Large-scale clinical trials of vitamin D supple-
mentation are ongoing [13,14,17]. Despite food fortifica-
tion and dietary supplementation, some studies have
observed that low vitamin D status is still relatively
common in the US [18] while a large portion of the
interperson variation in serum 25-hydroxyvitamin D
(25(OH)D) levels is unexplained [19,20].
Magnesium, the second most abundant intracellular
cation, plays a critical role in the synthesis and metabo-
lism of parathyroid hormone (PTH) and vitamin D




























Figure 1 Magnesium and metabolism of vitamin D. PTH, parathyroid hof three major enzymes determining 25(OH)D level
[22-25] and vitamin D binding protein [23] are magne-
sium dependent (Figure 1). Magnesium deficiency,
which leads to reduced 1,25(OH)2 vitamin D and im-
paired PTH response [23], has been implicated in ‘mag-
nesium-dependent vitamin-D-resistant rickets’ [21].
Magnesium supplementation substantially reversed the
resistance to vitamin D treatment [21]. Interestingly, a
study conducted among osteoporosis patients showed
much higher prevalence rates of magnesium deficiency
or insufficiency among people with insufficient 25(OH)D
than those with sufficient 25(OH)D [26]. Two small
clinical trials of magnesium-deficient patients [23,27]
found that magnesium infusion alone led to a non-
significant increase in 1,25(OH)2D and 25(OH)D [23]
whereas magnesium infusion plus oral vitamin D
substantially increased both serum 25(OH)D and 1,25
(OH)2D [27]. These findings suggest a potential inter-
action between vitamin D and magnesium treatmentsDietary Sources
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atural sources:
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ormone; UVB, ultraviolet B; VDBP, vitamin D binding protein.
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D status.
We hypothesize that magnesium intake alone and par-
ticularly its interaction with vitamin D intake contribute
to serum 25(OH)D status and tested this novel hypothesis
utilizing data from the National Health and Nutrition
Examination Survey (NHANES) 2001 to 2006. Further-
more, previous studies reported that serum 25(OHD) con-
centrations were associated with reduced risks of total
mortality, particularly mortality due to colorectal cancer
[28] and CVD [4,29]. We hypothesize that the inverse as-
sociations between serum 25(OH)D and risk of mortality
are modified by intake level of magnesium and tested this
hypothesis using the NHANES III cohort.
Methods
Participants
The 2001 to 2006 NHANES and the NHANES III were
reviewed and approved by the National Center for
Health Statistics (NCHS) Institutional Review Board
(IRB) (Hyattsville, MD, USA). A detailed description of
the study design has been published elsewhere [30,31].
To investigate if dietary magnesium alone and its inter-
action with vitamin D intake contribute to serum 25
(OH)D levels, we utilized data from the NHANES 2001
to 2006, which was conducted during years 2001 to 2006
by the NCHS of the Centers for Disease Control and
Prevention (CDC) (Atlanta, GA, USA). This is a nation-
ally representative and recent sample among the civilian,
non-institutionalized US population. Thus, the status of
serum 25(OH)D represents the current vitamin D status
of US population. Furthermore, serum PTH data are
available only in the NHANES conducted during 2003
to 2006. We limited our study population to 12257 par-
ticipants aged ≥20 years with serum 25(OH)D, reliable
dietary data, and negative for pregnancy test. However,
no follow-up of mortality outcomes were conducted for
NHANES 2001 to 2006. The mortality outcomes have
been prospectively followed in the NHANES III cohort
for which baseline data and blood collection were
conducted during 1988 to 1994 among a nationally
representative sample of US adults. Included in the
NHANES III cohort were those aged ≥17 years with 25
(OH)D measurements (n = 16819). The participants
were followed for mortality status from baseline until
December 31, 2006. Thus, we used the NHANES III
cohort to examine the modifying effects of magnesium
intake on the associations between serum 25(OH)D and
risk of mortality. Although the NHANES III cohort is
suitable for the investigation of the associations between
serum 25(OH)D and mortality outcomes, no serum
PTH data are available. NHANES III was approved by
the National Center for Health Statistics (NCHS) Insti-
tutional Review Board (IRB) and documented consentwas obtained from participants. The NCHS IRB (before
2003)/and the NCHS Research Ethics Review Board
(ERB) (year 2003 and after) approved the NHANES
2001 to 2006 (protocol #98-12 for the NHANES 2001 to
2004 and protocol #2005-06 for the NHANES 2005 to
2006).
Blood sample collection and measures of serum 25(OH)D
Over 88% of the 2001 to 2006 NHANES participants
and about 90% of the NHANES III participants donated
a spot blood sample. Measurements of serum 25(OH)D
were performed at the NCH, CDC, Atlanta, GA using a
radioimmunoassay (RIA) kit (Diasorin Inc., Stillwater
MN, USA) [32] and the coefficients of variations (CV)
were 13% to 19% in the NHANES III and 10% to 13% in
the NHANES 2001 to 2006 [29]. Serum PTH concentra-
tions were measured using the ECL/Origen electroche-
miluminescent process (Elecsys 1010 system, Roche
Diagnostics, Indianapolis, IN, USA) and CV was less
than 10%. Data were available only for the NHANES
2003 to 2006.
Outcomes
We have utilized the cut-off points as defined in the re-
cently issued Institute of Medicine (IOM) report to de-
fine vitamin D deficiency and insufficiency [33]. We
classified the participants in the NHANES 2001 to 2006
into the following three categories: (1) participants who
had IOM recommended vitamin D level (serum 25(OH)
D ≥20 ng/ml (50 nmol/l)); (2) participants who had
insufficient vitamin D (serum 25(OH)D ≥12 ng/ml
(30 nmol/l) but below 20 ng/ml (50 nmol/l)); and (3)
participants who had vitamin D deficiency (serum 25
(OH)D <12 ng/ml (30 nmol/l)). In addition to Institute
of Medicine’s recommendation, the other reason we
used 20 ng/ml as the cut-off point is that the median
value of serum 25(OH)D for the NHANES 2001 to 2006
was 21.0 ng/mg, which is very close to 20 ng/ml.
In the NHANES III cohort, mortality outcomes were
determined by using probabilistic linkage with the Na-
tional Death Index (NDI). For mortality due to CVD or
colorectal cancer, participants who died of other diseases
or were not known deceased, were censored at the date
of death or December 31, 2006, whichever was earlier.
Nutrient intake assessments
Daily dietary intake data were obtained from 24-h diet-
ary recalls and 30-day supplement interviews, which are
described in detail elsewhere [34]. Only one 24-h recall
was conducted in NHANES III and from 2001 to 2002.
To keep intake information consistent through the study
period only the first dietary recall for all subjects was
utilized in the present analysis. Only dietary recall data
with a status of ‘reliable’ were used in the analysis.
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D, and calcium were obtained from the response to a
dietary supplement questionnaire.
Statistical analysis
We performed statistical analyses using PROC Survey in
SAS 9.2 software (SAS Institute, Cary, NC, USA) to esti-
mate variance after incorporating the weights for the
sample population in NHANES.
Covariates were compared among three groups with
differing vitamin D status (Table 1). Any covariate that
significantly differed among groups was considered as a
potential confounding factor. In particular, those con-
founders that altered the estimate of association by 10% or
more were retained in the final models (see footnotes to
Tables 2 and 3). Other factors, such as use of phosphorus,
potassium, and retinol, did not materially alter the risk es-
timates. Multivariate adjusted odds ratios (ORs) and 95%
confidence intervals (CIs) for vitamin D deficiency and in-
sufficiency were calculated. Stratified analyses by potential
effect modifiers and tests for multiplicative interactions
using the Wald test were conducted.
Hazard ratios (HR) were estimated in Cox propor-
tional hazard regression models to examine whether the
associations between serum 25(OH)D and risk of mor-
tality differed by intake level of total magnesium, using
the data from the NHANES III cohort. The same cut-off
points for serum 25(OH)D were used as those in the
published report [28]. We adjusted for the same
confounding factors as we did for vitamin D deficiency
and insufficiency analyses. All reported P values were
two-sided. P values of <0.05 were considered statistically
significant in all analyses.
In Table 4, we present the associations between serum
25(OH)D and risk of mortality within two strata (<264
mg/day and ≥264 mg/day) of magnesium intake. How-
ever, this is only for data presentation purpose. In statis-
tical modeling, we have used continuous variables for
both serum 25(OH)D and intakes of magnesium in the
tests for interactions between serum 25(OH)D and in-
takes of magnesium in relation to total mortality, mor-
tality due to cardiovascular disease and mortality due to
colorectal cancer. We chose 264 mg/day as the cut-off
point presented in Table 4 based on both statistical
power consideration and biological support. We have a
limited sample size for colorectal cancer mortality
outcome. By using a median magnesium intake of 264
mg/day, we could maximize the sample size, and, thus,
the power to detect association between vitamin D levels
and mortality outcomes in both strata. Furthermore, 264
mg/day is very close to the 265 mg/day, the estimated
average requirements (EAR) for women and so it gave
us the opportunity to evaluate the relationship to the
EAR [35].Results
Selected demographic characteristics and potential
confounding factors by the three categories of serum 25
(OH)D status are shown in Table 1. Compared to the
Estimate Average Requirements (EAR, intake levels for
vitamin D (400 IU/day) and magnesium (330 mg/day)
recommended by the US Food and Nutrition Board of
the Institute of Medicine), the vitamin D normal group
generally met the recommended intake levels for both
vitamin D and magnesium whereas the average intake
levels of these nutrients were significantly lower in the
vitamin D-insufficient group and much lower among the
vitamin D-deficient group.
After adjusting for confounding factors, the ORs (95%
CI) for vitamin D deficiency and insufficiency were 0.10
(0.06 to 0.17) and 0.37 (0.27 to 0.51) comparing the
highest quartile intake of total vitamin D versus the low-
est (Ptrend <0.001) (Table 2). The corresponding ORs
(95% CI) were 0.34 (0.21 to 0.56) and 0.62 (0.46 to 0.82)
for total magnesium intake (Ptrend <0.001), respectively.
In addition, we found that both dietary and supplemen-
tal intakes of vitamin D and magnesium were signifi-
cantly inversely associated with risks of vitamin D
deficiency and insufficiency.
In stratified analyses by intake of vitamin D and other
factors related to vitamin D status (Table 3), we found
intake of magnesium significantly interacted with intake
of vitamin D in relation to both vitamin D deficiency
(Pinteraction, <0.001) and insufficiency (Pinteraction, <0.001).
The inverse association between magnesium intake and
risk of vitamin D deficiency only appeared significant
among those older than 50 years or with serum PTH
level being in the highest or lowest tertile category.
Meanwhile, the inverse associations between magnesium
intake and risk of vitamin D insufficiency were statisti-
cally significant only among people at high risk of
vitamin D insufficiency, such as those whose samples
were collected during winter (at southern latitude), those
with vitamin D intake below the median, women, non-
Hispanic Blacks, obese individuals or those with the
PTH levels in the highest tertile.
As reported previously, high levels of serum 25(OH)D
were associated with a reduced risk of mortality due to
all-cause CVD [4,29,36], and colorectal cancer [28]. We
found that the inverse associations for higher serum 25
(OH)D with risks of total mortality and mortality due to
CVD were only statistically significant among those with
magnesium intake above the median (Table 4). Although
the test for interaction was not statistically significant
for total mortality, it was statistically significant for mor-
tality due to CVD (Pinteraction, 0.03). Sample size was
small for mortality due to colorectal cancer. None of the
associations, including the main association, were statis-
tically significant. However, the association pattern in
Table 1 Selected characteristics of the study participants by serum 25(OH)D levels, National Health and Nutrition
Examination Survey (NHANES) 2001 to 2006
Charactersa Normal, n = 6962 Insufficiency, n = 3620 Deficiency, n = 1575 P valueb
Serum 25(OH)D (ng/ml), mean (SE) 28.5 (0.2) 16.1 (0.2) 8.8 (0.1) <0.001
Age (years), mean (SE) 47.0 (0.4) 46.7 (0.4) 46.2 (0.6) <0.001
Male, n (%) 3711 (51.2) 1833 (47.7) 696 (38.4) <0.001
Body mass index (kg/m2), mean (SE) 27.3 (0.1) 29.6 (0.2) 31.5 (0.4) <0.001
Month of blood collection, n (%)
1 November to 30 April (winter) 2,688 (34.4) 1,980 (50.7) 999 (57.6) <0.001
1 May to 31 October (summer) 4,274 (65.6) 1,640 (49.3) 676 (42.4)
Education, n (%)
Less than high school 1,694 (14.8) 1,194 (21.8) 621 (28.5) <0.001
High school 1,729 (25.3) 872 (26.3) 384 (25.4)
Greater than high school 3,535 (59.9) 1,550 (51.9) 667 (46.1)
Race/ethnicity, n (%)
Non-Hispanic Caucasian 4,812 (84.5) 1,390 (59.5) 316 (33.9) <0.001
Non-Hispanic Black 558 (3.5) 965 (17.0) 906 (44.8)
Hispanic 1,394 (8.6) 1,091 (16.5) 394 (14.1)
Others 198 (3.4) 174 (7.1) 59 (7.1)
Family poverty income ratio, n (%)
<1 929 (9.7) 661 (15.6) 358 (20.0) <0.001
1 to 4 4,181 (61.5) 2,230 (63.6) 1,031 (65.7)
≥5 1,507 (28.8) 516 (20.8) 181 (14.3)
Smoker, n (%)
Non-smoker 3,407 (49.5) 1,856 (50.0) 869 (50.0) <0.001
Former smoker 1,914 (24.8) 833 (21.0) 303 (16.3)
Current smoker 1,637 (25.7) 926 (29.0) 500 (33.8)
Alcohol user, n (%)
Non-drinker 784 (15.0) 555 (21.5) 293 (24.2) <0.001
Former drinker 559 (10.3) 382 (14.3) 187 (14.1)
Current drinker 3,139 (74.8) 1,452 (64.2) 639 (61.7)
Physical activity during the day, n (%)
Sit and not walk about very much 1,512 (21.2) 960 (27.0) 541 (32.9) <0.001
Walk a lot 3,584 (50.4) 1,904 (50.5) 857 (49.2)
Light work 1,276 (20.5) 497 (15.2) 202 (13.9)
Heavy work 582 (8.0) 254 (7.3) 73 (4.0)
Leisure time physical activity
(Metabolic equivalent/h/week), mean (SE)
1,292.4 (52.2) 788.5 (55.6) 674.2 (53.1) <0.001
Users of supplement containing vitamin D (%) 3,258 (47.2) 1,018 (30.4) 202 (12.5) <0.001
Users of supplement containing Ca (%) 3,860 (57.1) 1,380 (42.6) 351 (22.3) <0.001
Users of supplement containing Mg (%) 3,040 (45.1) 1,072 (32.0) 235 (14.9) <0.001
Energy-adjusted nutrient intakesc, mean (SE)
Protein (g/day) 82.0 (0.5) 80.1 (0.7) 77.8 (1.3) <0.01
Carbohydrate (g/day) 258.5 (1.4) 262.4 (1.7) 261.6 (2.9) 0.135
Fat (g/day) 80.7 (0.5) 80.3 (0.6) 81.2 (0.9) 0.93
Calcium (mg/day) 929.0 (8.4) 805.2 (9.1) 690.3 (13.6) <0.001
Magnesium (mg/day) 293.1 (2.2) 266.6 (2.9) 252.4 (4.2) <0.001
Deng et al. BMC Medicine 2013, 11:187 Page 5 of 14
http://www.biomedcentral.com/1741-7015/11/187
Table 1 Selected characteristics of the study participants by serum 25(OH)D levels, National Health and Nutrition
Examination Survey (NHANES) 2001 to 2006 (Continued)
Vitamin D (IU/day) 196 (8.0) 160 (8.0) 116 (8.0) <0.001
Total calcium (mg/day)d 1,168.8 (12.6) 935.4 (12.3) 748.5 (15.9) <0.001
Total magnesium (mg/day)d 344.2 (3.5) 297.3 (3.2) 262.4 (4.4) <0.001
Total vitamin D (IU/day)d 376 (8.0) 276 (8.0) 152 (8.0) <0.001
aValues are present as weighted means (SE) and unweighted frequencies (weighted percentages, %).
bRao-Scott χ2 test for categorical data and analysis of variance (ANOVA) test for continuous variables.
cValues are energy-adjusted means (SE).
dTotal calcium, magnesium and vitamin D intake from foods and supplements.
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that for total mortality and mortality due to CVD.
Discussion
Consistent with our hypothesis, we observed that high
intake of total, dietary or supplemental magnesium was
independently and significantly associated with reduced
risks of both vitamin D deficiency and insufficiency. Fur-
thermore, intake of magnesium significantly interacted
with intakes of vitamin D in relation to both vitamin D
deficiency and insufficiency. In the NHANES III cohort,
a population-based prospective study, we found the in-
verse associations of serum 25(OH)D with mortality,
particularly mortality due to CVD and colorectal cancer,
were modified by magnesium intake, and the inverse as-
sociations were primarily present among those with
magnesium intake above the median. In addition, we
found the inverse association between magnesium intake
and risk of vitamin D deficiency primarily occurred in
those who had the highest or the lowest tertile of PTH
level; while the inverse association between total magne-
sium intake and vitamin D insufficiency primarily
appeared among populations at high risk of vitamin D
insufficiency. To the best of our knowledge, this is the
first study to examine the interaction between vitamin D
and magnesium in association to mortality; and this is
the first study to suggest a potential independent contri-
bution of total magnesium intake and its interaction
with vitamin D intake to vitamin D status in the general
population.
Under normal physiologic conditions, 25(OH)D is de-
rived primarily from endogenous synthesis via exposure
of skin to sunlight because few natural foods contain
vitamin D except by fortification or supplementation
(see Figure 1). Vitamin D3 or D2 is transferred to the
liver via vitamin D binding protein (VDBP) and
converted to 25(OH)D by 25-hydroxylase and subse-
quently carried to the kidney by VDBP and converted to
1,25(OH)2D by 1α-hydroxylase enzyme. Both 25(OH)D
and 1,25(OH)2D can be converted by 24-hydroxylase to
the 24,25(OH)2D or 1,24,25(OH)3D, respectively [37].
Therefore, 25(OH)D levels are primarily determined by
VDBP, 25-hydroxylase, 1α-hydroxylase and 24-hydroxy-lase activity, a fact that has recently been substantiated
by a genome-wide association study [38]. Based on pre-
vious in vitro studies, magnesium status regulates both
1α-hydroxylase and 24-hydroxylase activity [22,24].
Previous studies indicated both VDBP [23] and 25-
hydroxylase [25,39] might also be magnesium depen-
dent. Therefore, magnesium would be expected to play
an important role in 25(OH)D metabolism.
A previous clinical study found that parenteral magne-
sium treatment without vitamin D replacement in 23
magnesium-deficient patients led to a 12% rise in 25
(OH)D and 30% increase in 1,25(OH)2D, but both
changes were not statistically significant [23]. In a subse-
quent study of five magnesium-deficient patients, intra-
muscular treatment with magnesium alone also did not
significantly increase 25(OH)D, but magnesium infusion
together with pharmacological dose of 25(OH)D sub-
stantially increased both 25(OH)D and 1,25(OH)2D
among patients with magnesium deficiency. One inter-
pretation is that magnesium treatment does not affect
25(OH)D status [23,27]. However, we postulate that
several factors may have contributed to the insignificant
increase in 25(OH)D status. First, the subjects participat-
ing in these studies had low concentrations of 25(OH)D
and 1,25(OH)2D as well as pre-vitamin D3 and vitamin D3
as a result of limited sunlight exposure, underlying disease
and/or lack of oral supplementation. Therefore, concen-
trations of 25(OH)D and 1,25(OH)2D did not substantially
increase during short-term magnesium repletion because
pre-vitamin D3 was not available in sufficient amounts.
Second, there was a modest increase in the conversion of
25(OH)D to 1,25(OH)2D and, thus, a reduction in 25(OH)
D level was expected due to this conversion [22]. Finally,
the sample size in these two studies was very small par-
ticularly if the direct effect of magnesium treatment on
vitamin D status is only moderate.
We found that high magnesium intake was also associ-
ated with a reduced risk of vitamin D deficiency or in-
sufficiency. We believe that this observation is the result
of the interaction between various metabolic pathways
that regulate 25(OH)D levels. Previous studies have
shown that endogenously synthesized vitamin D3 is
transferred almost completely by VDBP to liver and this
Table 2 Multivariate-adjusted odds ratios (95% CIs)a for associations between total intakes of vitamin D and
magnesium and risk of vitamin D deficiency and insufficiency, National Health and Nutrition Examination Survey




N OR (95% CI) N OR (95% CI)
Total vitamin D intake (IU/day)
Q1 <114 1,741 1,005 1.00 1,450 1.00
Q2 114 to 307 1,740 446 0.55 (0.40 to 0.75) 1,086 0.75 (0.62 to 0.91)
Q3 308 to 539 1,741 152 0.22 (0.15 to 0.34) 665 0.55 (0.44 to 0.69)
Q4 ≥540 1,740 72 0.10 (0.06 to 0.17) 419 0.37 (0.27 to 0.51)
P for trend <0.001 <0.001
Dietary vitamin D intake (IU/day)
Q1 <57.8 1,741 764 1.00 1,183 1.00
Q2 57.8 to 137 1,740 468 0.71 (0.55 to 0.91) 997 0.86 (0.71 to 1.05)
Q3 138 to 261 1,741 279 0.54 (0.40 to 0.72) 807 0.72 (0.59 to 0.88)
Q4 ≥262 1,740 164 0.29 (0.20 to 0.41) 633 0.69 (0.56 to 0.86)
P for trend <0.001 <0.001
Supplemental vitamin D intake (IU/day)
Non-user 3,704 1,473 1.00 2,602 1.00
1 to 239 809 93 0.32 (0.20 to 0.50) 377 0.84 (0.68 to 1.03)
240 to 399 331 19 0.29 (0.13 to 0.64) 109 0.57 (0.38 to 0.87)
≥400 2,118 90 0.19 (0.11 to 0.33) 532 0.40 (0.29 to 0.53)
P for trend <0.001 <0.001
Total magnesium intake (mg/day)
Q1 <225 1,749 876 1.00 1,362 1.00
Q2 225 to 310 1,733 392 0.67 (0.50 to 0.90) 907 0.78 (0.61 to 1.00)
Q3 311 to 419 1,737 245 0.43 (0.30 to 0.63) 758 0.73 (0.59 to 0.89)
Q4 ≥420 1,743 162 0.34 (0.21 to 0.56) 593 0.62 (0.46 to 0.82)
P for trend <0.001 <0.001
Dietary magnesium intake (mg/day)
Q1 <195 1,754 726 1.00 1,255 1.00
Q2 195 to 268 1,732 432 0.75 (0.58 to 0.97) 893 0.75 (0.62 to 0.90)
Q3 269 to 363 1,741 297 0.68 (0.47 to 0.99) 777 0.69 (0.55 to 0.87)
Q4 ≥364 1,735 220 0.43 (0.26 to 0.70) 695 0.61 (0.45 to 0.83)
P for trend 0.002 0.002
Supplemental magnesium intake (mg/day)
Non-user 3,922 1,440 1.00 2,548 1.00
1 to 49 669 109 0.53 (0.34 to 0.81) 334 1.14 (0.91 to 1.43)
50 to 99 506 43 0.35 (0.17 to 0.71) 205 0.80 (0.53 to 1.22)
≥100 1,865 83 0.30 (0.17 to 0.52) 533 0.68 (0.52 to 0.88)
P for trend <0.001 0.008
aSurvey logistic regression models used to estimate odds ratios and 95% confidence intervals. Models adjusted for age, sex, body mass index (BMI), educational
attainment, race, household income, smoking status, alcohol use, physical activity, month of blood collection, dietary intakes of total energy and total calcium
intake. Models were also adjusted for total intake of vitamin D or magnesium mutually.
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Table 3 Odds ratios (95% CI)a for vitamin D deficiency and insufficiency stratified by the median of vitamin D intake or
season, National Health and Nutrition Examination Survey (NHANES) 2001 to 2006
Magnesium intake, mg/day Controls,
N
Deficiency Insufficiency
N OR (95% CI) N OR (95% CI)
Vitamin D intake <308 (IU/day)
Q1 <225 1,359 834 1.00 1,218 1.00
Q2 225 to 310 940 328 0.79 (0.58 to 1.07) 650 0.89 (0.69 to 1.15)
Q3 311 to 419 697 184 0.64 (0.46 to 0.91) 426 0.78 (0.63 to 1.08)
Q4 ≥420 485 105 0.58 (0.35 to 0.97) 242 0.71 (0.47 to 1.07)
P for trend 0.01 <0.05
Vitamin D intake ≥308 (IU/day)
Q1 <225 390 42 1.00 144 1.00
Q2 225 to 310 793 64 1.09 (0.47 to 2.55) 257 0.94 (0.62 to 1.42)
Q3 311 to 419 1,040 61 0.76 (0.30 to 1.88) 332 1.19 (0.80 to 1.77)
Q4 ≥420 1,258 57 0.71 (0.24 to 2.11) 351 0.96 (0.60 to 1.55)
P for trend 0.97 0.67
P for interaction <0.001 <0.001
Non-vitamin D supplement user
Q1 <225 1,292 812 1.00 1,160 1.00
Q2 225 to 310 958 332 0.81 (0.57 to 1.14) 651 0.91 (0.70 to 1.18)
Q3 311 to 419 793 205 0.59 (0.40 to 0.88) 462 0.80 (0.63 to 1.02)
Q4 ≥420 661 124 0.60 (0.35 to 1.00) 329 0.81 (0.55 to 1.19)
P for trend 0.02 0.18
Vitamin D supplement user
Q1 <225 457 64 1.00 202 1.00
Q2 225 to 310 775 60 1.23 (0.59 to 2.56) 256 0.80 (0.53 to 1.20)
Q3 311 to 419 944 40 1.05 (0.41 to 1.68) 296 0.96 (0.65 to 1.41)
Q4 ≥420 1,082 38 0.91 (0.35 to 2.36) 264 0.73 (0.49 to 1.10)
P for trend 0.56 0.40
P for interaction 0.47 0.37
Winter and Southern latitude
Q1 <225 664 493 1.00 726 1.00
Q2 225 to 310 691 239 0.63 (0.47 to 0.85) 495 0.73 (0.57 to 0.92)
Q3 311 to 419 653 156 0.49 (0.30 to 0.78) 422 0.89 (0.74 to 1.07)
Q4 ≥420 680 111 0.54 (0.28 to 1.02) 337 0.57 (0.41 to 0.78)
P for trend 0.03 <0.01
Summer and Northern latitude
Q1 <225 1,085 383 1.00 636 1.00
Q2 225 to 310 1,042 153 0.95 (0.64 to 1.41) 412 0.91 (0.66 to 1.26)
Q3 311 to 419 1,084 89 0.61 (0.43 to 0.86) 336 0.73 (0.56 to 0.96)
Q4 ≥420 1,063 51 0.33 (0.20 to 0.55) 256 0.85 (0.61 to 1.19)
P for trend 0.001 0.35
P for interaction 0.55 0.21
Age <50 (years)
Q1 <225 862 465 1.00 726 1.00
Q2 225 to 310 821 209 0.74 (0.49 to 1.11) 495 0.83 (0.60 to 1.16)
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Table 3 Odds ratios (95% CI)a for vitamin D deficiency and insufficiency stratified by the median of vitamin D intake or
season, National Health and Nutrition Examination Survey (NHANES) 2001 to 2006 (Continued)
Q3 311 to 419 831 150 0.63 (0.35 to 1.13) 422 0.84 (0.62 to 1.13)
Q4 ≥420 892 110 0.67 (0.32 to 1.42) 337 0.73 (0.50 to 1.08)
P for trend 0.26 0.15
Age ≥50 (years)
Q1 <225 1,085 383 1.00 636 1.00
Q2 225 to 310 1,042 153 0.85 (0.50 to 1.37) 412 0.86 (0.63 to 1.16)
Q3 311 to 419 1,084 89 0.43 (0.24 to 0.77) 336 0.79 (0.57 to 1.10)
Q4 ≥420 1,063 51 0.24 (0.11 to 0.49) 256 0.71 (0.46 to 1.10)
P for trend <0.01 0.81
P for interaction 0.07 0.41
Male
Q1 <225 712 283 1.00 519 1.00
Q2 225 to 310 854 164 0.64 (0.41 to 1.00) 466 1.12 (0.78 to 1.61)
Q3 311 to 419 995 143 0.39 (0.21 to 0.74) 439 0.90 (0.65 to 1.26)
Q4 ≥420 1,150 106 0.33 (0.16 to 0.69) 409 0.95 (0.59 to 1.52)
P for trend 0.001 0.54
Female
Q1 <225 1,037 593 1.00 843 1.00
Q2 225 to 310 879 228 0.85 (0.61 to 1.21) 441 0.71 (0.54 to 0.93)
Q3 311 to 419 742 102 0.63 (0.37 to 1.05) 319 0.83 (0.64 to 1.07)
Q4 ≥420 593 56 0.47 (0.25 to 0.87) 184 0.60 (0.43 to 0.82)
P for trend 0.16 0.14
P for interaction 0.11 0.17
Non-Hispanic Black
Q1 <225 181 530 1.00 442 1.00
Q2 225 to 310 163 181 0.51 (0.34 to 0.76) 229 0.74 (0.53 to 1.03)
Q3 311 to 419 110 115 0.44 (0.26 to 0.74) 175 0.53 (0.33 to 0.88)
Q4 ≥420 104 81 0.43 (0.27 to 0.68) 119 0.64 (0.39 to 1.04)
P for trend <0.001 <0.05
Non-Hispanic Caucasian and others
Q1 <225 1,568 346 1.00 920 1.00
Q2 225 to 310 1,570 212 0.91 (0.65 to 1.28) 678 0.86 (0.67 to 1.10)
Q3 311 to 419 1,627 130 0.66 (0.45 to 0.97) 583 0.87 (0.67 to 1.10)
Q4 ≥420 1,639 81 0.52 (0.29 to 0.95) 474 0.76 (0.58 to 0.99)
P for trend <0.05 0.27
P for interaction 0.305 0.82
BMI <25 (kg/m2)
Q1 <225 631 172 1.00 336 1.00
Q2 225 to 310 611 90 1.04 (0.51 to 2.12) 339 0.92 (0.61 to 1.40)
Q3 311 to 419 606 58 0.84 (0.40 to 1.76) 189 1.00 (0.70 to 1.44)
Q4 ≥420 608 41 0.51 (0.23 to 1.15) 162 0.77 (0.47 to 1.27)
P for trend 0.13 0.45
BMI ≥25 to <30 (kg/m2)
Q1 <225 605 232 1.00 448 1.00
Deng et al. BMC Medicine 2013, 11:187 Page 9 of 14
http://www.biomedcentral.com/1741-7015/11/187
Table 3 Odds ratios (95% CI)a for vitamin D deficiency and insufficiency stratified by the median of vitamin D intake or
season, National Health and Nutrition Examination Survey (NHANES) 2001 to 2006 (Continued)
Q2 225 to 310 632 106 0.71 (0.43 to 1.15) 316 0.77 (0.51 to 1.17)
Q3 311 to 419 661 75 0.50 (0.29 to 0.86) 266 0.63 (0.50 to 0.79)
Q4 ≥420 677 46 0.47 (0.22 to 1.01) 213 0.73 (0.48 to 1.13)
P for trend 0.02 0.06
BMI ≥30 (kg/m2)
Q1 <225 463 440 1.00 532 1.00
Q2 225 to 310 457 177 0.63 (0.35 to 1.14) 341 0.82 (0.63 to 1.06)
Q3 311 to 419 441 108 0.46 (0.24 to 0.88) 288 0.83 (0.59 to 1.15)
Q4 ≥420 424 69 0.42 (0.19 to 0.96) 202 0.63 (0.44 to 0.91)
P for trend 0.02 0.02
P for interaction 0.23 0.13
PTH <32 (pg/ml)
Q1 <225 322 63 1.00 179 1.00
Q2 225 to 310 369 39 0.42 (0.18 to 1.02) 109 0.72 (0.42 to 1.24)
Q3 311 to 419 363 21 0.17 (0.07 to 0.43) 107 0.77 (0.47 to 1.28)
Q4 ≥420 392 19 0.22 (0.07 to 0.73) 100 0.74 (0.38 to 1.42)
P for trend <0.01 0.46
PTH ≥32 to <46 (pg/ml)
Q1 <225 378 136 1.00 271 1.00
Q2 225 to 310 382 66 1.20 (0.66 to 2.21) 195 0.94 (0.73 to 1.22)
Q3 311 to 419 406 54 1.19 (0.53 to 2.66) 181 0.85 (0.59 to 1.23)
Q4 ≥420 414 33 1.11 (0.36 to 3.42) 131 0.79 (0.55 to 1.15)
P for trend 0.85 0.24
PTH ≥46 (pg/ml)
Q1 <225 390 375 1.00 447 1.00
Q2 225 to 310 382 157 0.73 (0.48 to 1.10) 297 0.93 (0.68 to 1.28)
Q3 311 to 419 382 95 0.52 (0.28 to 0.95) 209 0.78 (0.60 to 1.01)
Q4 ≥420 365 50 0.28 (0.14 to 0.53) 159 0.57 (0.35 to 0.92)
P for trend 0.01 0.41
P for interaction 0.73 0.53
Parathyroid hormone (PTH) laboratory results were only available from the NHANES 2003 to 2006.
aSurvey logistic regression models used to estimate odds ratios and 95% confidence intervals. Models were adjusted for age, sex, body mass index (BMI),
educational attainment, race, household income, smoking status, alcohol use, physical activity, month of blood collection, dietary intakes of total energy, total
intake of calcium and vitamin D.
Deng et al. BMC Medicine 2013, 11:187 Page 10 of 14
http://www.biomedcentral.com/1741-7015/11/187transport is slow, leading to a more sustained plasma
vitamin D3, compared to that from supplementation of
vitamin D, which is delivered to the liver by non-VDBP
carriers in the plasma [40]. VDBP may also be an im-
portant determinant of serum 25(OH)D concentration,
particularly when dietary intake of vitamin D is low. In
the study by Rude et al., the concentration of VDBP was
lower among 11 magnesium-deficient patients and
significantly increased to normal after magnesium treat-
ment without vitamin D supplementation [23]. There-
fore, it is possible that an improvement in magnesium
status leads to an increase in VDBP synthesis and, inturn, an elevated transport of vitamin D3 to the liver and
25(OH)D to the kidney.
The critical roles of magnesium in the synthesis of
VDBP, PTH, 25(OH)D and 1,25(OH)2D may partially ex-
plain why the inverse associations between serum 25
(OH)D and risk of total mortality and mortality due to
colorectal cancer and CVD primarily existed among
those with magnesium intake above the median. High
magnesium may increase the availability of 1,25 (OH)2D
through activating the synthesis of 25(OH)D and 1,25
(OH)2D and increasing the transfer to target tissues by
elevating vitamin D binding protein (VDBP) (Figure 1).
Table 4 Hazard ratios (HRs)a and 95% CIs for total mortality in the National Health and Nutrition Examination Survey
(NHANES) III (1988 to 2006)
Magnesium intake (mg/day) Serum vitamin D level (ng/ml) P for trend
<20 20 to 31 32 to 39 ≥40
Total mortality
Total Cases 1,274 1,547 558 324
HR (95% CI) 1.00 0.83 (0.74 to 0.94) 0.80 (0.69 to 0.93) 0.79 (0.66 to 0.93) <0.01
<264 Cases 848 786 249 143
HR (95% CI) 1.00 0.89 (0.74 to 1.08) 0.87 (0.69 to 1.08) 0.87 (0.64 to 1.20) 0.23
≥264 Cases 426 761 309 181
HR (95% CI) 1.00 0.77 (0.64 to 0.92) 0.73 (0.58 to 0.93) 0.70 (0.57 to 0.88) <0.01
P for interaction 0.96
Cardiovascular mortality
Total Cases 574 656 253 132
HR (95% CI) 1.00 0.73 (0.62 to 0.86) 0.77 (0.61 to 0.99) 0.73 (0.56 to 0.97) 0.04
<264 Cases 386 346 112 57
HR (95% CI) 1.00 0.83 (0.66 to 1.04) 0.88 (0.61 to 1.28) 0.91 (0.61 to 1.35) 0.45
≥264 Cases 188 310 141 75
HR (95% CI) 1.00 0.59 (0.44 to 0.80) 0.65 (0.44 to 0.95) 0.57 (0.38 to 0.87) <0.05
P for interaction 0.03
Colorectal cancer mortality
Total Cases 32 34 12 8
HR (95% CI) 1.00 0.84 (0.36 to 2.00) 0.80 (0.31 to 2.05) 0.50 (0.15 to 1.73) 0.31
<264 Cases 19 17 3 3
HR (95% CI) 1.00 1.17 (0.39 to 3.56) 0.79 (0.17 to 3.75) 0.85 (0.17 to 4.12) 0.73
≥264 Cases 13 17 9 5
HR (95% CI) 1.00 0.55 (0.16 to 1.85) 0.67 (0.17 to 2.64) 0.28 (0.03 to 2.25) 0.29
P for interaction 0.15
aA Cox’s proportional hazards model was performed with the SURVEYPHREG procedure to estimate odds ratios and 95% confidence intervals. Models were
adjusted for age, race, sex, BMI, education attainment, household income, smoking status, alcohol use, physical activity, month of blood collection, intakes of total
energy, phosphorus, calcium and magnesium.
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previous clinical studies that magnesium supplementa-
tion substantially reversed the resistance to vitamin D
treatment among magnesium-deficient patients [21].
Previous studies found PTH level was elevated when
serum 25(OH)D was under 20 ng/ml [41]. In the current
study, we found magnesium intake was associated with a
reduced risk of vitamin D insufficiency or deficiency
only among those in the highest or the lowest tertile of
PTH. This finding is possible because magnesium plays
an important role in PTH regulation. This finding is also
supported by observations made in a study of 30 women
with osteoporosis that were investigated for magnesium
deficiency using a magnesium tolerance test [26]. The
subjects were divided into three groups: ten with vitamin
D insufficiency (low vitamin D and raised PTH); ten
with functional hypoparathyroidism (low vitamin D and
low/low normal PTH); and ten who were vitamin Dreplete (normal vitamin D and normal PTH). All ten
subjects with functional hypoparathyroidism were found
to be magnesium deficient; five magnesium-deficient
and five magnesium-insufficient patients were found in
the subjects with vitamin D insufficiency, and only one
magnesium-deficient and four magnesium-insufficient
patients were found in the vitamin D replete group.
Furthermore, intravenous magnesium infusion led to a
significant rise in PTH in the group with functional
hypoparathyroidism and a reduction in PTH in the sub-
jects with vitamin D insufficiency.
A number of previous studies have examined the asso-
ciations between magnesium intake with risk of stroke
[42,43] and coronary heart disease [43,44], however, the
results have been inconsistent in these previous studies.
Two meta-analyses of prospective studies found that
magnesium intake was related to a significantly reduced
risk of stroke [42,43]. However, the inverse association
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sium/day increment). Likewise, a previous meta-analysis
found that magnesium intake was non-significantly in-
versely associated with coronary heart disease with a
pooled RR (95% confidence intervals (CIs)) of 0.86 (0.67
to 1.10) for the highest intake versus the lowest intake
category [43]. In the current study, we found that the
HR (95% CIs) for risk of mortality due to cardiovascular
disease was 0.88 (0.61 to 1.26) for the highest quartile
intake of magnesium versus the lowest quartile intake,
which is very close to that in previous studies. Several
previous studies have also evaluated the associations be-
tween magnesium intake and risk of colorectal cancer
and results have also not been consistent [45]. A very re-
cent meta-analysis found that every 100 mg/day increase
in magnesium intake was related to 12% reduced risk of
colorectal cancer (RR: 0.88; 95% CI 0.81 to 0.97). In the
current study, we found that the HR (95% CIs) for risk
of mortality due to colorectal cancer was 0.76 (0.15 to
3.86) for the highest quartile intake of magnesium versus
the lowest quartile intake, which is also consistent with
those from previous cohort studies. The significant inter-
action between serum vitamin D and magnesium intake in
relation to mortality for cardiovascular disease and colo-
rectal cancer may also explain some inconsistencies in
previous studies which examined the associations of mag-
nesium intake alone with risk of cardiovascular disease
and colorectal cancer.
A strength of our study is that it is based on
NHANES, a population-based study with nationally rep-
resentative samples. As with all prevalent case–control
studies, one concern is that the temporal sequence may
not be clear. However, it is unlikely that serum vitamin
D status led to high or low intake of magnesium or vita-
min D. Furthermore, the analysis of data from the
NHANES III, a population-based prospective cohort,
provides additional indications that magnesium interacts
with vitamin D in relation to mortality. It is possible that
people who consumed a high level of magnesium may
also have a healthy lifestyle (for example, more physical
activity and higher proportion of dietary supplement
users). Supplement users may consume a high level of
vitamin D from supplements while outdoor physical ac-
tivity is related to an increasing production of 25(OH)D
from sunlight exposure. We have adjusted for physical
activity and intake of vitamin D from both diet and sup-
plement in all analyses. Furthermore, we have conducted
stratified analyses by physical activity and use of supple-
ment. We found, unlike intake of magnesium, physical
activity and use of supplements did not significantly or
marginally significantly modify the association between
serum 25(OH)D and mortality. Finally, although mul-
tiple 24-h dietary recalls are used as a gold standard
measure in nutritional epidemiologic studies, a one-time24-h dietary recall may not capture long-term dietary
exposure. However, similar to dietary vitamin D and
supplemental vitamin D intake, we found both dietary
intake of magnesium (based on 24-h dietary recall) and
magnesium from supplementation intake (derived from
30-day supplement questionnaire) significantly contrib-
uted to serum vitamin D status. Moreover, total intake
of magnesium significantly interacted with intake of vita-
min D in relation to both magnesium deficiency and in-
sufficiency while total intake of magnesium modified the
association between serum vitamin D and mortality.
Since inter-day variation in magnesium intake is ran-
dom, any residual inter-day variation may lead to non-
differential misclassification, which usually biases the
result to the null. Thus, the true associations of magne-
sium intake with vitamin D status risk may be stronger
than those we observed. Our findings are not only bio-
logically plausible, but also remarkably consistent, indi-
cating our findings may not be solely due to chance. In
the current study, we did not have data for other param-
eters of the vitamin D/PTH axis (that is, serum PTH
and 1,25-dihydroxyvitamin D), which may indeed be af-
fected by magnesium status. Future studies are warranted
to examine if low magnesium status using dietary and
body status of magnesium affected both PTH levels and
1,25-dihydroxyvitamin D because this could serve as one
mechanism for the observed interaction between serum
25(OH)D and magnesium intake on mortality.
Conclusions
Our preliminary findings indicate it is possible that
magnesium intake alone or its interaction with vitamin
D intake may contribute to vitamin D status. The associ-
ations between serum 25(OH)D and risk of mortality
may be modified by the intake level of magnesium. Fu-
ture studies, including cohort studies and clinical trials,
are necessary to confirm the findings.
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